QLT hikes size of share buyback

The board of QLT approved an increase in the number of common shares the company (TSX:QLT; NASDAQ:QLTI) may purchase under its normal course issuer bid to 4,700,060, or 10% of the public float, from  2,731,534, or 5% of the outstanding stock on Oct. 28, 2009. The 12-month buyback program ends on Nov. 2, 2010.  The [...]

QLT has positive outcomes treating LCA

QLT (NASDAQ:QLTI; TSX:QLT) has released “positive outcomes” from interim results of the first three subjects enrolled in a Phase 1b clinical proof-of-concept study of its QLT091001 treatment for Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease. LCA leads to retinal dysfunction and significant visual impairment beginning at birth.  Based on the positive results [...]

Cormark raises QLT price target

On the heels of QLT (NASDAQ:QLTI; TSX:QLT) reaching a 52-week high of $5.45 (U.S.) on Wednesday, Cormark Securities raised its price target to $6.50 from $5.35, maintaining a “buy” rating on the stock. In a new report, analyst David Dean writes that QLT expects to report data this year from two clinical programs, which “do [...]